Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Laekna, Inc.

Equities

2105

KYG5340S1093

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:07 2024-06-03 am EDT 		5-day change 1st Jan Change
6.61 HKD -1.93% Intraday chart for Laekna, Inc. -5.97% -66.78%
May. 30 Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4% MT
May. 30 Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4%
MT
Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer
CI
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer
PR
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%
MT
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer
CI
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug
MT
Lekna, Inc. Obtains IND Approval from the CDE for LAE102
CI
Laekna Releases 2023 ESG Report
PR
Laekna Scores FDA Nod for Obesity Drug LAE102
MT
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102
CI
Laekna Shrinks Loss in Fiscal 2023
MT
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug
MT
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration
CI
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities
MT
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102
CI
Laekna, Inc. Announces Management Changes
CI
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34%
MT
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China
CI
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2105 Stock
  4. News Laekna, Inc.